New scan could spot breast cancer markers without a needle
NCT ID NCT05412446
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new imaging agent called 99mTc-ADAPT6 in 30 women with breast cancer that had spread to lymph nodes. The agent is designed to attach to HER2 proteins on cancer cells, allowing doctors to see them on a SPECT scan. The goal was to see if the scan results matched standard biopsy tests for HER2 status. If it works, this could offer a less invasive way to check HER2 levels in tumors and lymph nodes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m-labelled ADAPT6 (99mTc-ADAPT6)
What this could lead to
If successful, this imaging method could help doctors see HER2 levels in breast cancer without needing a biopsy, guiding treatment decisions.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to all patients. The imaging agent may not match biopsy results perfectly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tomsk NRMC
Tomsk, Russia